Pernix Therapeutics Reports Second Quarter 2017 Financial Results and Provides Business Update
July 27, 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial results...
Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results
July 20, 2017 16:52 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., July 20, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced certain...
Pernix Therapeutics Added to Russell Microcap® Index
June 28, 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), announced today that it has been added to the Russell Microcap® index...
Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update
May 15, 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial results...
Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength
May 01, 2017 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that, due to...
Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
March 28, 2017 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced financial...
Novan Reshapes Executive Management Team
March 22, 2017 09:20 ET
|
Novan, Inc.
Former Quintiles Executive Paula Brown Stafford Joins Novan as Chief Development Officer Stanley Hollenbach Promoted to Senior Vice President of Research and Development William L. Hodges Appointed...
Pernix Therapeutics Provides Update on Arbitration
February 03, 2017 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today provided an...
Pernix Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
November 10, 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
Net Revenue Increased 13% Sequentially Over Second Quarter 2016Prescription Volumes Grew Sequentially and Year-Over-Year for All Three Core Brands, Treximet®, Zohydro ER® with BeadTek™ and...
Pernix Therapeutics Announces Distribution of TREXIMET® 10/60 mg (sumatriptan 10mg and naproxen sodium 60 mg) Dose For Use in Pediatric Patients
September 28, 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced...